Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives

Overview

Journal Curr Treat Options Oncol

Specialty Oncology

Date 2020 Feb 13

PMID 32048063

Citations 2

Authors

Nasr Alrabadi

Razan Haddad

Ahmed K Alomari

Affiliations

Soon will be listed here.

Abstract

Liquid biopsies are still far from widely implanted in the clinical arena. Issues related to the added sensitivity of this test beyond conventional methods have not been fully resolved. Additionally, issues related to the specificity of these results especially as many cancers may share common mutation need further investigations. One way to resolve this may include the development and testing of large gene panels to add higher specificity. On the other hand, further studies are needed to support the idea that ctDNA or circulating tumor cells may constitute a better representation of the tumor subpopulation that is capable of metastasizing, which will strongly support its clinical value. Finally, survival studies showing a positive impact of this technology will also justify its widespread implementation in clinical practice.

Citing Articles

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples.

Guma J, Pena K, Riu F, Guilarte C, Hernandez A, Lucia C Cancers (Basel). 2022; 14(23).

PMID: 36497340 PMC: 9739663. DOI: 10.3390/cancers14235859.

Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR.

Giunta E, De Falco V, Vitiello P, Guerrera L, Suarato G, Napolitano R Cancers (Basel). 2022; 14(13).

PMID: 35804825 PMC: 9265107. DOI: 10.3390/cancers14133053.

References

Hong X, Sullivan R, Kalinich M, Kwan T, Giobbie-Hurder A, Pan S . Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018; 115(10):2467-2472. PMC: 5877960. DOI: 10.1073/pnas.1719264115. View

Pardini B, Sabo A, Birolo G, Calin G . Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies. Cancers (Basel). 2019; 11(8). PMC: 6721601. DOI: 10.3390/cancers11081170. View

Lim S, Lee J, Diefenbach R, Kefford R, Rizos H . Liquid biomarkers in melanoma: detection and discovery. Mol Cancer. 2018; 17(1):8. PMC: 5772714. DOI: 10.1186/s12943-018-0757-5. View

Lee J, Long G, Menzies A, Lo S, Guminski A, Whitbourne K . Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncol. 2018; 4(5):717-721. PMC: 5885201. DOI: 10.1001/jamaoncol.2017.5332. View

Fattore L, Ruggiero C, Pisanu M, Liguoro D, Cerri A, Costantini S . Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death Differ. 2018; 26(7):1267-1282. PMC: 6748102. DOI: 10.1038/s41418-018-0205-5. View

Aya-Bonilla C, Gray E, Manikandan J, Freeman J, Zaenker P, Reid A . Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. Cancers (Basel). 2019; 11(2). PMC: 6406574. DOI: 10.3390/cancers11020157. View

Fattore L, Costantini S, Malpicci D, Ruggiero C, Ascierto P, Croce C . MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017; 8(13):22262-22278. PMC: 5400662. DOI: 10.18632/oncotarget.14763. View

Felisiak-Golabek A, Inaguma S, Kowalik A, Wasag B, Wang Z, Zieba S . SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma. Appl Immunohistochem Mol Morphol. 2017; 26(1):40-45. PMC: 5719500. DOI: 10.1097/PAI.0000000000000500. View

Mumford S, Towler B, Pashler A, Gilleard O, Martin Y, Newbury S . Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine. Biomolecules. 2018; 8(2). PMC: 6022922. DOI: 10.3390/biom8020021. View

10.

Syeda M, Wiggins J, Corless B, Spittle C, Karlin-Neumann G, Polsky D . Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma. Methods Mol Biol. 2019; 2055:155-180. DOI: 10.1007/978-1-4939-9773-2_7. View

11.

Koeppel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E . Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017; 12(11):e0188174. PMC: 5697854. DOI: 10.1371/journal.pone.0188174. View

12.

Huang J, Chikeka I, Hornyak T . Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence. Dermatol Clin. 2016; 35(1):85-93. PMC: 5391772. DOI: 10.1016/j.det.2016.08.001. View

13.

Khagi Y, Goodman A, Daniels G, Patel S, Sacco A, Randall J . Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017; 23(19):5729-5736. PMC: 5678984. DOI: 10.1158/1078-0432.CCR-17-1439. View

14.

Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern M . Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol. 2018; 15(10):639-650. DOI: 10.1038/s41571-018-0074-3. View

15.

Bisschop C, Ter Elst A, Bosman L, Platteel I, Jalving M, van den Berg A . Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. Melanoma Res. 2017; 28(2):96-104. PMC: 5844592. DOI: 10.1097/CMR.0000000000000421. View

16.

Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti M . Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 2017; 88:1-9. PMC: 5769519. DOI: 10.1016/j.ejca.2017.10.029. View

17.

Hellwig S, Nix D, Gligorich K, OShea J, Thomas A, Fuertes C . Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS One. 2018; 13(7):e0197333. PMC: 6059400. DOI: 10.1371/journal.pone.0197333. View

18.

Bai X, Fisher D, Flaherty K . Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways. Nat Rev Clin Oncol. 2019; 16(9):549-562. PMC: 7185899. DOI: 10.1038/s41571-019-0204-6. View

19.

Alrabadi N, Gibson N, Curless K, Cheng L, Kuhar M, Chen S . Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. Mod Pathol. 2018; 32(3):330-337. DOI: 10.1038/s41379-018-0161-0. View

20.

Sieben C, Sturmlechner I, van de Sluis B, van Deursen J . Two-Step Senescence-Focused Cancer Therapies. Trends Cell Biol. 2018; 28(9):723-737. PMC: 6102047. DOI: 10.1016/j.tcb.2018.04.006. View